Higher bioavailability of isoflavones after a single ingestion of a soya-based supplement than a soya-based food in young healthy males

British Journal of Nutrition

Volumn 99, Issue 2, 2008, Pages 333-344

  Vergne, Sébastien ^a,b   Bennetau pelissero, Catherine ^a   Lamothe, Valérie ^a   Chantre, Philippe ^b   Potier, Mylène ^a   Asselineau, Julien ^c   Perez, Paul ^c   Durand, Marlène ^d   Moore, Nicholas ^e   Sauvant, Patrick ^a  

^a ENITA de Bordeaux   (France)

^b Department of Arkopharma   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Bioavailability; Isoflavones; Soya

Indexed keywords

DAIDZEIN; GENISTEIN; ISOFLAVONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEESE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; SOYBEAN; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 38049161292     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114507803953     Document Type: Article

References (43)

1. Cassidy A, Albertazzi P, Lise Nielsen I, et al. (2006) Critical review of health effects of soyabean phyto-oestrogens in postmenopausal women. Proc Nutr Soc 65, 76-92.
2. Usui T (2006) Pharmaceutical prospects of phytoestrogens. Endocr J 53, 7-20.
3. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G & Cassidy A (2003) Bioavailability of phyto-oestrogens. Br J Nutr 89, Suppl. 1, S45-S58.
4. Cassidy A, Bingham S & Setchell KDR (1994) Biological effects of soy protein rich isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 60, 333-340.
5. Choi MS & Rhee KC (2006) Production and processing of soybeans and nutrition and safety of isoflavone and other soy products for human health. J Med Food 9, 1-10.
6. Xu X, Harris KS, Wang HJ, Murphy PA & Hendrich S (1995) Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr 125, 2307-2315.
7. Piskula MK, Yamakoshi J & Iwai Y (1999) Daidzein and genistein but not their glucosides are absorbed from the rat stomach. FEBS Lett 447, 287-291.
8. Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR & Williamson G (1998) Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. FEBS Lett 436, 71-75.
9. Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, Kirschner AS & Heubi JE (2002) Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 76 447-453.
10. Axelson M, Sjovall J, Gustafsson BE & Setchell KD (1984) Soya - a dietary source of the non-steroidal oestrogen equol in man and animals. J Endocrinol 102, 49-56.
11. Adlercreutz H, Musey PI, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G & Hase T (1986) Identification of lignans and phytoestrogens in urine of chimpanzees. Clin Chim Acta 158, 147-154.
12. Nurmi T, Mazur W, Heinonen S, Kokkonen J & Adlercreutz H (2002) Isoflavone content of the soy based supplements. J Pharm Biomed Anal 28, 1-11.
13. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A & Heubi JE (2001) Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131, 1362S-1375S.
14. Busby MG, Jeffcoat AR, Bloedon LT, et al. (2002) Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 75 126-136.
15. Bloedon LT, Jeffcoat AR, Lopaczynski W, et al. (2002) Safety and pharmacokinetics of purified soy isoflavones: Single-dose administration to postmenopausal women. Am J Clin Nutr 76, 1126-1137.
16. Richelle M, Pridmore-Merten S, Bodenstab S, Enslen M & Offord EA (2002) Hydrolysis of isoflavone glycosides to aglycones by beta-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in postmenopausal women. J Nutr 132, 2587-2592.
17. Vergne S, Titier K, Bernard V, et al. (2007) Bioavailability and urinary excretion of isoflavones in humans: Effects of soy-based supplements formulation and equol production. J Pharm Biomed Anal 43, 1488-1494.
18. Anupongsanugool E, Teekachunhatean S, Rojanasthien N, Pongsatha S & Sangdee C (2005) Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women. BMC Clin Pharmacol 5, 2.
19. de Pascual-Teresa S, Hallund J, Talbot D, Schroot J, Williams CM, Bugel S & Cassidy A (2006) Absorption of isoflavones in humans: Effects of food matrix and processing. J Nutr Biochem 17, 257-264.
20. Cassidy A, Brown JE, Hawdon A, Faughnan MS, King LJ, Millward J, Zimmer-Nechemias L, Wolfe B & Setchell KD (2006) Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods. J Nutr 136, 45-51.
21. Kano M, Takayanagi T, Harada K, Sawada S & Ishikawa F (2006) Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J Nutr 136, 2291-2296.
22. Murphy PA, Song T, Buseman G & Barua K (1997) Isoflavones in soy-based infant formulas. J Agric Food Chem 45, 4635-4638.
23. Bennetau-Pelissero C, Le Houerou C, Lamothe V, Le Menn F, Babin P & Bennetau B (2000) Synthesis of haptens and conjugates for ELISAs of phytoestrogens. Development of the immunological tests. J Agric Food Chem 48, 305-311.
24. Bennetau-Pelissero C, Arnal-Schnebelen B, Lamothe V, Sauvant P, Sagne JL, Verbruggen MA, Mathey J & Lavialle O (2003) ELISA as a new method to measure genistein and daidzein in food and human fluids. Food Chemistry 82, 645-658.
25. Le Houerou C, Bennetau-Pelissero C, Lamothe V, Le Menn F, Babin P & Bennetau B (2000) Syntheses of novel hapten-protein conjugates for production of highly specific antibodies to formononetin, daidzein and genistein. Tetrahedron 56, 295-301.
26. Mathey J, Lamothe V, Coxam V, Potier M, Sauvant P & Pelissero CB (2006) Concentrations of isoflavones in plasma and urine of post-menopausal women chronically ingesting high quantities of soy isoflavones. J Pharm Biomed Anal 41, 957-965.
27. Grizzle JE (1965) The two-period change-over design and its use in clinical trials. Biometrics 21, 467-480.
28. Hubert J, Berger M & Dayde J (2005) Use of a simplified HPLC-UV analysis for soyasaponin B determination: Study of saponin and isoflavone variability in soybean cultivars and soy-based health food products. J Agric Food Chem 53, 3923-3930.
29. Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen BS, Helferich WG & Katzenellenbogen JA (2004) Equol, a natural estrogenic metabolite from soy isoflavones: Convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 12, 1559-1567.
30. Verbruggen MA & van Roojen JJM (2001) Analysis of isoflavones-results of a ring test. Fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, 4-7 November 2001. San Diego, California, USA.
31. Erdman JW Jr, Badger TM, Lampe JW, Setchell KD & Messina M (2004) Not all soy products are created equal: Caution needed in interpretation of research results. J Nutr 134, 1229S-1233S.
32. AFSSA-AFSSAPS (French Food Safety Agency - French Health Products Safety Agency) (2005) The Safety and Benefits of dietary phytoestrogens - Recommendations. Joint AFSSA-AFSSAPS expert consultation. AFSSA-AFSSAPS report ISBN 2-11-095443-4, Nancy, France, Imprimerie Blayec. Available at: http://www.afssa.fr.
33. Messina M, Nagata C & Wu AH (2006) Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 55, 1-12.
34. Ritchie MR, Cummings JH, Morton MS, Michael Steel C, Bolton-Smith C & Riches AC (2006) A newly constructed and validated isoflavone database for the assessment of total genistein and daidzein intake. Br J Nutr 95, 204-213.
35. Xu X, Wang HJ, Murphy PA & Hendrich S (2000) Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. J Nutr 130, 798-801.
36. Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, Jakate AS, Creutzinger V & Heubi JE (2003) Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr 133, 1027-1035.
37. Yamamoto S, Sobue T, Kobayashi M, Sasaki S & Tsugane S (2003) Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 95, 906-913.
38. Watanabe S, Yamaguchi M, Sobue T, Takahashi T, Miura T, Arai Y, Mazur W, Wahala K & Adlercreutz H (1998) Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 128, 1710-1715.
39. Izumi T, Piskula MK, Osawa S, Obata A, Tobe K, Saito M, Kataoka S, Kubota Y & Kikuchi M (2000) Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 130, 1695-1699.
40. Zubik L & Meydani M (2003) Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. Am J Clin Nutr 77, 1459-1465.
41. Franke AA, Custer LJ & Hundahl SA (2004) Determinants for urinary and plasma isoflavones in humans after soy intake. Nutr Cancer 50 141-154.
42. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R & Kinae N (2000) Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 130, 2243-2250.
43. Faure ED, Chantre P & Mares P (2002) Effects of a standardized soy extract on hot flushes: A multicenter, double-blind, randomized, placebo-controlled study. Menopause 9, 329-334.